Junshi Bio (01877.HK) announced the receipt of a drug registration certificate issued by the National Medical Products Administration. The company's product, Toripalimab (commodity name: Tuoyi), in combination with paclitaxel injection for the first-line treatment of recurrent or metastatic PD-L1 positive triple-negative breast cancer patients confirmed by sufficient testing and evaluation, has been approved for a new indication. This is the tenth indication for Toripalimab approved in Mainland China.
君實生物(01877.HK)特瑞普利單抗新適應症上市申請獲批
Junshi Bio (01877.HK) received approval for the new indication of Trastuzumab injection.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.